欧美成一级-欧美成在人线a免费-欧美传媒影-欧美大逼逼-欧美大成色www永久网站婷-欧美大胆a级视频

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Quikin CAR-T Platform


The Quikin CAR-T Platform (Quikin CART) generates T cell products with gene knockout and stable integration of CAR cassette in one step through CRISPR gene editing technology. As a new generation of CAR-T platform, it has several advantages, including simplified manufacturing process, shortened preparation time, higher product uniformity and avoiding the risk of tumorigenesis caused by random integration. The product with integration of anti-CD19 CAR cassette into PD1?locus combines PD1 immune checkpoint inhibition with CART anti-tumor activity. This platform has the potential to prepare enhanced CAR-T cells with gene knockout of multiple immune checkpoints, rapidly produce universal CAR-T cells and prepare dynamically regulated CAR-T cells with high safety, thus providing strong technical support for future improvement of CAR-T cells.


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 国产一区二区精品尤物 | 亚洲成a人片在线观看 | 国产尤物尤物在线看 | 日韩色偷拍一区二区三区 | 无码少妇免费一区二区三区 | 日韩精品在线视频 | 一本色道久久综合亚洲精品 | 九九影院日韩欧美精品 | 欧美一区二区三区激情在线 | 蜜桃视频| 国产精品国 | 欧美成人国产在线观看 | 国产精品码一区 | 欧美日韩在线视频 | 伊人精品成人久久综合97 | 久久不射 | 2025中文字幕在线观看 | 日本一区二区中文字幕久久 | 免费精品国产自产拍在线观看 | 日韩综合在线观看 | 97人人超碰国产精品最新老片 | 人亲久久精品天天中文字幕 | 亚洲国产精品悠悠久久琪琪 | 亚洲国产精品日韩av不卡在线 | 久久永久免费人妻精品 | 九九视频免费在线观 | 国产免费久久久久久免费看 | 国产v片在线播放免费无码 国产v天堂无码一区二区三区 | a级毛片无码久久精品免费 a级免费观看 | 国产va免费精品天天干夜夜添 | 亚洲性影院在线看 | 亚洲熟妇无码av不卡在线播放 | 欧美成人精品欧美一级乱黄 | 久久天天躁狠狠躁夜 | 国产成人精品毛片曰本亚洲 | 国内精品久久久久久99蜜桃 | 亚洲国产精品综合久久20 | 成年禁止18网站永久入口 | 亚洲不卡v一区二区无码免费 | 亚洲国产91 | 国产精品黄在线观看免费 |